DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
0301 basic medicine
QH301-705.5
Receptors, Cell Surface
612
Respiratory Mucosa
[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry
Cell Line
Jurkat Cells
03 medical and health sciences
Antigens, CD
Chlorocebus aethiops
Animals
Humans
Lectins, C-Type
Biology (General)
Lung
Vero Cells
[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM]
Molecular Biology/Structural Biology [q-bio.BM]
SARS-CoV-2
COVID-19
RC581-607
3. Good health
Mannose-Binding Lectins
Mannosides
Spike Glycoprotein, Coronavirus
glycomimetics; DC-SIGN; Covid-19; SARS-CoV2;
Immunologic diseases. Allergy
Cell Adhesion Molecules
Research Article
Protein Binding
DOI:
10.1371/journal.ppat.1009576
Publication Date:
2021-05-20T17:30:07Z
AUTHORS (14)
ABSTRACT
The efficient spread of SARS-CoV-2 resulted in a unique pandemic in modern history. Despite early identification of ACE2 as the receptor for viral spike protein, much remains to be understood about the molecular events behind viral dissemination. We evaluated the contribution of C-type lectin receptors (CLRS) of antigen-presenting cells, widely present in respiratory mucosa and lung tissue. DC-SIGN, L-SIGN, Langerin and MGL bind to diverse glycans of the spike using multiple interaction areas. Using pseudovirus and cells derived from monocytes or T-lymphocytes, we demonstrate that while virus capture by the CLRs examined does not allow direct cell infection, DC/L-SIGN, among these receptors, promote virus transfer to permissive ACE2+Vero E6 cells. A glycomimetic compound designed against DC-SIGN, enable inhibition of this process. These data have been then confirmed using authentic SARS-CoV-2 virus and human respiratory cell lines. Thus, we described a mechanism potentiating viral spreading of infection.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (97)
CITATIONS (138)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....